Power3 Files Four Patents on Biomarkers for Early Detection of Neurodegenerative Disease

THE WOODLANDS, Texas, Feb. 15, 2005 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company, announced that the Company has filed four utility patent applications for examination by the United States Patent and Trademark Office, relating to 'Biomarkers for Neurological Disease' used in various diagnostic test procedures. These applications correspond with provisional patents filed by Power3 Medical Products in 2004.

The filed patents aim to protect the diagnostic testing procedures utilized by the Company in identifying and tracking specific protein biomarkers that could lead to the early detection and diagnosis of neurodegenerative disease. The latest patent applications add to Power3's IP portfolio consisting of numerous patents filed over the last few years for disease biomarkers and diagnostic assays.

Steven B. Rash, Chief Executive Officer of Power3 Medical, commented, "Power3 continues to move forward in the patent application process for the Company's neurodegenerative disease early detection test. We are very pleased with our progress in the neurodegenerative field to date and are applying for these patents based on the scientific merit of our diagnostic tests as well as the commercialization potential of the biomarkers."

About Power3 Medical Products, Inc.

Power3 Medical Products is a leading edge biotechnology company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases that the Company's proprietary technology can detect in patients. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease.

Safe Harbor Statement

All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.


Contact Data